Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
- Author
- SCHER, Howard I1 ; BEER, Tomasz M6 ; HUNG, David11 ; HIRMAND, Mohammad11 ; SEELY, Lynn11 ; MORRIS, Michael J1 ; DANILA, Daniel C1 ; HUMM, John3 ; LARSON, Steve2 ; FLEISHER, Martin4 ; SAWYERS, Charles L5 7 ; HIGANO, Celestia S8 ; ANAND, Aseem1 ; TAPLIN, Mary-Ellen9 ; EFSTATHIOU, Eleni10 ; RATHKOPF, Dana1 ; SHELKEY, Julia1 ; YU, Evan Y8 ; ALUMKAL, Joshi6
[1] Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
[2] Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
[3] Nuclear Medicine Service, Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
[4] Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
[5] Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
[6] Oregon Health and Science University Knight Cancer Institute, Portland, OR, United States
[7] Howard Hughes Medical Institute, Chevy Chase, MD, United States
[8] University of Washington, Seattle, WA, United States
[9] Dana-Farber Cancer Institute, Boston, MA, United States
[10] MD Anderson Cancer Center, Houston, TX, United States
[11] Medivation, San Francisco, CA, United States
Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium - Source
Lancet (British edition). 2010, Vol 375, Num 9724, pp 1437-1446, 10 p ; ref : 30 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Activité biologique Anticancéreux Cancer de la prostate Castration Essai clinique phase I Essai clinique phase II Médecine Résistance Cancer Pathologie de l'appareil génital mâle Pathologie de l'appareil urinaire Pathologie de la prostate Tumeur maligne
- Keyword (en)
- Biological activity Antineoplastic agent Prostate cancer Castration Phase I trial Phase II trial Medicine Resistance Cancer Male genital diseases Urinary system disease Prostate disease Malignant tumor
- Keyword (es)
- Actividad biológica Anticanceroso Cáncer de la próstata Castración Ensayo clínico fase I Ensayo clínico fase II Medicina Resistencia Cáncer Aparato genital macho patología Aparato urinario patología Prostata patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B14 Nephrology. Urinary tract diseases / 002B14D Tumors of the urinary system / 002B14D02 Urinary tract. Prostate gland
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20B Male genital diseases / 002B20B02 Tumors
- Discipline
- Generalities in medical sciences Gynecology. Andrology. Obstetrics Nephrology. Urinary tract diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 22686059
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(10)60172-9 
https://dx.doi.org/10.1016/S0140-6736(10)60172-9
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)60172-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9724\";s:8:\"\u0000*\u0000spage\";s:4:\"1437\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SCHER\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Howard I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:14:\"BEER, Tomasz M\";i:1;s:11:\"HUNG, David\";i:2;s:17:\"HIRMAND, Mohammad\";i:3;s:11:\"SEELY, Lynn\";i:4;s:17:\"MORRIS, Michael J\";i:5;s:16:\"DANILA, Daniel C\";i:6;s:10:\"HUMM, John\";i:7;s:13:\"LARSON, Steve\";i:8;s:16:\"FLEISHER, Martin\";i:9;s:18:\"SAWYERS, Charles L\";i:10;s:18:\"HIGANO, Celestia S\";i:11;s:12:\"ANAND, Aseem\";i:12;s:18:\"TAPLIN, Mary-Ellen\";i:13;s:17:\"EFSTATHIOU, Eleni\";i:14;s:14:\"RATHKOPF, Dana\";i:15;s:14:\"SHELKEY, Julia\";i:16;s:10:\"YU, Evan Y\";i:17;s:14:\"ALUMKAL, Joshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)60172-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9724\";s:8:\"\u0000*\u0000spage\";s:4:\"1437\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SCHER\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Howard I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:14:\"BEER, Tomasz M\";i:1;s:11:\"HUNG, David\";i:2;s:17:\"HIRMAND, Mohammad\";i:3;s:11:\"SEELY, Lynn\";i:4;s:17:\"MORRIS, Michael J\";i:5;s:16:\"DANILA, Daniel C\";i:6;s:10:\"HUMM, John\";i:7;s:13:\"LARSON, Steve\";i:8;s:16:\"FLEISHER, Martin\";i:9;s:18:\"SAWYERS, Charles L\";i:10;s:18:\"HIGANO, Celestia S\";i:11;s:12:\"ANAND, Aseem\";i:12;s:18:\"TAPLIN, Mary-Ellen\";i:13;s:17:\"EFSTATHIOU, Eleni\";i:14;s:14:\"RATHKOPF, Dana\";i:15;s:14:\"SHELKEY, Julia\";i:16;s:10:\"YU, Evan Y\";i:17;s:14:\"ALUMKAL, Joshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)60172-9\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)60172-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9724\";s:8:\"\u0000*\u0000spage\";s:4:\"1437\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SCHER\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Howard I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:14:\"BEER, Tomasz M\";i:1;s:11:\"HUNG, David\";i:2;s:17:\"HIRMAND, Mohammad\";i:3;s:11:\"SEELY, Lynn\";i:4;s:17:\"MORRIS, Michael J\";i:5;s:16:\"DANILA, Daniel C\";i:6;s:10:\"HUMM, John\";i:7;s:13:\"LARSON, Steve\";i:8;s:16:\"FLEISHER, Martin\";i:9;s:18:\"SAWYERS, Charles L\";i:10;s:18:\"HIGANO, Celestia S\";i:11;s:12:\"ANAND, Aseem\";i:12;s:18:\"TAPLIN, Mary-Ellen\";i:13;s:17:\"EFSTATHIOU, Eleni\";i:14;s:14:\"RATHKOPF, Dana\";i:15;s:14:\"SHELKEY, Julia\";i:16;s:10:\"YU, Evan Y\";i:17;s:14:\"ALUMKAL, Joshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)60172-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9724\";s:8:\"\u0000*\u0000spage\";s:4:\"1437\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SCHER\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Howard I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:14:\"BEER, Tomasz M\";i:1;s:11:\"HUNG, David\";i:2;s:17:\"HIRMAND, Mohammad\";i:3;s:11:\"SEELY, Lynn\";i:4;s:17:\"MORRIS, Michael J\";i:5;s:16:\"DANILA, Daniel C\";i:6;s:10:\"HUMM, John\";i:7;s:13:\"LARSON, Steve\";i:8;s:16:\"FLEISHER, Martin\";i:9;s:18:\"SAWYERS, Charles L\";i:10;s:18:\"HIGANO, Celestia S\";i:11;s:12:\"ANAND, Aseem\";i:12;s:18:\"TAPLIN, Mary-Ellen\";i:13;s:17:\"EFSTATHIOU, Eleni\";i:14;s:14:\"RATHKOPF, Dana\";i:15;s:14:\"SHELKEY, Julia\";i:16;s:10:\"YU, Evan Y\";i:17;s:14:\"ALUMKAL, Joshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)60172-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9724\";s:8:\"\u0000*\u0000spage\";s:4:\"1437\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"SCHER\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Howard I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:14:\"BEER, Tomasz M\";i:1;s:11:\"HUNG, David\";i:2;s:17:\"HIRMAND, Mohammad\";i:3;s:11:\"SEELY, Lynn\";i:4;s:17:\"MORRIS, Michael J\";i:5;s:16:\"DANILA, Daniel C\";i:6;s:10:\"HUMM, John\";i:7;s:13:\"LARSON, Steve\";i:8;s:16:\"FLEISHER, Martin\";i:9;s:18:\"SAWYERS, Charles L\";i:10;s:18:\"HIGANO, Celestia S\";i:11;s:12:\"ANAND, Aseem\";i:12;s:18:\"TAPLIN, Mary-Ellen\";i:13;s:17:\"EFSTATHIOU, Eleni\";i:14;s:14:\"RATHKOPF, Dana\";i:15;s:14:\"SHELKEY, Julia\";i:16;s:10:\"YU, Evan Y\";i:17;s:14:\"ALUMKAL, Joshi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
